Pancreatic cancer comprises different subtypes, where most cases include ductal adenocarcinoma (PDAC). It is one of the deadliest tumor types, with a poor prognosis. In the majority of patients, th...
Despite many decades of research, pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to diagnose and treat effectively. Although there have been improvements in the 5...
as cancer therapy, effectively achieving this strategy in the clinic remains complex. In the... This approach is proposed following a clinical observation in pancreatic adenocarcinoma...
Pancreatic cancer has a dismal prognosis and only a few treatment options are available. In the European Union, pancreatic cancer classifies as a rare dis...
pancreatic cancer; therapeutic strategies 1. Drug Repurposing: An Attractive and Challenging Approach Drug repurposing has been emerging as an interesting alternative to the conventional...
Pancreatic ductal adenocarcinoma (PDAC) is responsible for 7.3% of all cancer deaths. Even though there is a steady increase in patient survival for most cancers over the decades, the patient survi...
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death worldwide. It is commonly diagnosed in advanced stages and therapeutic interventions are typically const...
Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, nonsurgical stage, making such patie...
The present disclosure provides a method for treating pancreatic cancer and limiting the over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients...
The present meta-analysis does not show significant improvements in survival for targeted drugs in advanced pancreatic cancer. The possible reason of these results could be linked to the biology of...